key: cord-1036323-436kavkc
authors: Guo, Jing-Jing; Yu, Yan-Hua; Ma, Xue-Ying; Liu, Ya-Nan; Fang, Qian; Qu, Pei; Guo, Jie; Lou, Jin-Li; Wang, Ya-Jie
title: A multiple-center clinical evaluation of a new real-time reverse transcriptase PCR diagnostic kit for SARS-CoV-2
date: 2020-10-28
journal: Future virology
DOI: 10.2217/fvl-2020-0299
sha: f91629b2d972dd05179555a7dec70a8c6bea54b9
doc_id: 1036323
cord_uid: 436kavkc

Aim: The outbreak of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has had serious repercussions worldwide. This study was aimed to evaluate the accuracy of a new kit for detection of SARS-CoV-2 compared with similar detection kit. Materials & methods: A total of 500 subjects were included and tested with both the new test and control kits. Clinical diagnosis results were taken as the reference standard. Results: Compared with clinical diagnosis, the sensitivity of the test kit was 82.64%, specificity was 98.45% and total coincidence rate was 90.80%. The total coincidence rate, sensitivity and specificity between control kit and clinical diagnosis were 89.20%, 78.10% and 99.61%, respectively. Conclusions: The new kit was comparable to the similar detection kit for detection of SARS-CoV-2 in sensitivity, specificity and total coincidence rate.

similar detection kit (control kit, Shanghai ZJ Bio-Tech Co. Ltd, Shanghai, China). Specimens were collected between February 14 and February 18, 2020, and were held at 4 • C if all testing could be completed within 24 h. 500 subjects (395 oropharyngeal swab specimens; 167 sputum specimens) with suspected or clinical diagnosis of SARS-CoV-2 or with history of close contact from three centers in China were enrolled in this study. Among these subjects, 62 underwent double sampling. Patients with fever, cough, chest discomfort/tightness and other clinical symptoms were also included in the study. The results of clinical diagnosis were taken as the reference standard. The clinical diagnosis of SARS-CoV-2 infection was according to the latest guideline of Diagnosis and Treatment of Pneumonitis Caused by SARS-CoV-2 (trial seventh version) published by the Chinse government [9] . Diagnosis was based on clinical history, laboratory, chest radiographic findings and nucleic acid-based assays. The remaining specimens for clinical testing were collected and tested with two RT-PCR diagnostic kits. This study was conducted in accordance with Declaration of Helsinki and Good Clinical Practice Guidelines and approved by the ethics committee institutional review board of each participating center.

The performance verification of the test kit was conducted according to the Measures for the Administration of Registration of In-Vitro Diagnostic Reagents, including lowest detection limit, freeze-thaw stability, cross-reactivity and anti-interference ability. The lowest detection limit for the test kit was determined as the lowest concentration with 90-95% of the tested samples in positive. The three batches of test kits were frozen (-20 ± 5 • C) and thawed 3, 6, 9, 10 or 11 times at 25 ± 2 • C, respectively, to verify the freeze-thaw stability. To evaluate potential crossreactivity, 56 pathogens with the same infection site or similar symptoms as SARS-CoV-2 were detected. These organisms included human coronavirus (229E, OC43, HKU1 and NL63), severe acute respiratory syndromerelated coronavirus (SARSr-CoV), seasonal influenza A (H1N1, H3N2, H5N1 and H7N9) viruses and adenovirus (type 1, 2, 3, 4, 5, 7, and 55), among others. Anti-interference ability was measured in the presence of various interfering substances. For this purpose, two independent oropharyngeal swabs and sputum specimens were spiked with potential interfering substances that could be collected with the sample. Interfering substances included 2.5%, 5.0% and 7.5% blood (v/v), mucoprotein (0.45, 0.9 or 1.35 mg/ml), beclomethasone (2.5 mg/ml), dexamethasone (5 μg/ml), phenylephrine (50%, v/v) and oxymetazoline (50%, v/v), for example.

Real-time PCR assay for screening of SARS-CoV-2 RNA was extracted from different specimens according to the manufacturer's instructions. Both RT-PCR kits targeted the ORF1ab and nucleoprotein gene regions. If two targets tested positive, the subject was considered to be laboratory confirmed. For the test kit developed by Beijing Applied Biological Technologies Co., a cycle threshold value (Ct-value) of 38 or less was considered a positive test, whereas a Ct-value greater than 40 was defined as a negative test. Specimens with a Ct-value of 38-40 need to be retested. If the repeated Ct-value was less than 40 and an obvious peak was observed, the retest was considered as positive. For the control kit developed by Shanghai ZJ Bio-Tech Co., a Ct-value less than 37 was defined as a positive test, whereas a Ct-value of 40 or more was considered as a negative test. Specimens with a Ct-value of 37-40 need to be retested. If the repeated Ct-value was less than 40 and an obvious peak was observed, the retest was considered positive. When both sputum and oropharyngeal swab specimens were collected from the same subject, sputum specimen was included in the final statistic.

All statistical analyses were performed by using SPSS version 22.0 (SPSS Institute, Chicago, IL, USA). Quantitative data were expressed as means ± SD. Qualitative data were expressed as number and percentage. Sensitivity (positive coincidence rate), specificity (negative coincidence rate), total coincidence rate, positive predictive value (PPV), negative predictive value (NPV) and Kappa index were used for degree of agreement of the two kits. Statistical significance was set at p < 0.05.

Performance verification of the test kit As shown in Table 1 , the positive rates of the three batches of kits were all 100% when the sample concentration were 1.0 × 10 3 , 5.0 × 10 2 and 2.0 × 10 2 , respectively. Therefore, the lowest detection limit was 2.0 × 10 2 copies/ml. The results obtained after 11 freeze-thaw cycles of the test kit showed no significant difference between the results obtained after 0 freeze-thaw cycles ( Table 2 ). In addition, there was no cross-reaction with other pathogens, and Negative (N1-N10) 10/10 10/10 10/10 10/10 10/10 10/10

ORF1ab no interference was observed with the interfering substances.

A total of 500 subjects (258 males, 242 females) were enrolled in this study from February 14 to February 18, 2020. The baseline characteristics of included subjects are shown in Table 3 . A total of 562 specimens were collected, including 395 oropharyngeal swabs specimens and 167 sputum specimens. A total of 62 subjects underwent double sampling. The age range of subjects was 0.75 (9 months)-93 years old. The majority of the subjects were aged 20-80 years, of which 40.8% subjects aged 20-40 years, 30.6% subjects aged 40-60 years, and 16.8% subjects aged 60-80 years. Among the 500 subjects, 94 had symptoms. The main symptoms of included subjects were fever (9.0%), pneumonia (2.6%), fatigue (2.0%), pulmonary infection (1.6%), cough (1.4%) and chest discomfort/tightness (1.4%). Table 4 , test kit results of 542 specimens were consistent with control kit (215 were positive, 327 were negative) and 20 specimens were inconsistent. The total coincidence rate between two kits was 96.44% (95% CI: 94.56 to 97.81), and the Kappa index was 0.9259 (p < 0.05), indicating the accuracy of test kit for detection of SARS-CoV-2 was comparable to control kit. Among the 20 inconsistent specimens, 18 were positive and 2 were negative by test kit. In addition, the experimental kit results of 15 specimens were consistent with clinical diagnosis (14 were positive, 1 was negative).

The results of subgroup analysis by age are shown in Table 5 

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

Clinical features and treatment of COVID-19 patients in northeast Chongqing

Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement

Multiple-centre clinical evaluation of an ultrafast single-tube assay for SARS-CoV-2 RNA

Frequency and distribution of chest radiographic findings in patients positive for COVID-19

Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection

Performance & quality evaluation of marketed COVID-19 RNA Detection Kits. medRxiv

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCOV RT-PCR assay for the qualitative detection of SARS-CoV-2 from upper respiratory tract specimens. medRxiv

Evaluation of enzyme-linked immunoassay and colloidal gold-immunochromatographic assay kit for detection of novel coronavirus (SARS-Cov-2) causing an outbreak of pneumonia (COVID-19). medRxiv

Real-time RT-PCR in COVID-19 detection: issues affecting the results

Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT?

Preliminary post-mortem COVID-19 evidence of endothelial injury and factor VIII hyperexpression

Clinical-forensic autopsy findings to defeat COVID-19 disease: a literature review

Laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections

The authors thank Beijing Youan Hospital and Beijing Ditan Hospital for providing data support.

 Guo filiations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.

This study was conducted in accordance with Declaration of Helsinki and Good Clinical Practice Guidelines, and approved by ethics committee institutional review board of each participating center (number: 2020003-01 and 2020029). All the specimens were remaining specimens after clinical testing, and the sensitive information such as the name of subjects was not presented in our study. Therefore, the informed consent of patients was exempted with the approval of ethics committee.

• The outbreak of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has caused serious harm worldwide. Therefore, accurate and rapid diagnosis of SARS-CoV-2 infection is extremely important to disrupt the transmission chain.

Biological Technologies Co. In this study, we aimed to evaluate the accuracy of the new kit for detection of SARS-CoV-2 compared with a similar detection kit. • The new test kit showed good performance in lowest detection limit, freeze-thaw stability, cross-reactivity and anti-interference ability. • Compared with clinical diagnosis, sensitivity of test kit was 82.64%, specificity was 98.45%, positive predictive value was 98.04%, negative predictive value was 85.81% and the total coincidence rate was 90.80%. • The total coincidence rate between control kit and clinical diagnosis was 89.20%, with sensitivity of 78.10%, specificity of 99.61%, positive predictive value of 99.47% and negative predictive value of 82.90%. • The Multiple Real-Time PCR Kit developed by Beijing Applied Biological Technologies Co. was comparable to the similar detection kit for detection of SARS-CoV-2 in sensitivity, specificity and total coincidence rate.